Browsing by author "Turner, Nicholas"
Now showing items 41-60 of 104
-
Evaluation of Cancer-Based Criteria for Use in Mainstream BRCA1 and BRCA2 Genetic Testing in Patients With Breast Cancer.
Kemp, Z; Turnbull, A; Yost, S; Seal, S; Mahamdallie, S; et al. (AMER MEDICAL ASSOC, 2019-05-03)IMPORTANCE: Increasing BRCA1 and BRCA2 (collectively termed herein as BRCA) gene testing is required to improve cancer management and prevent BRCA-related cancers. OBJECTIVE: To evaluate mainstream genetic testing using ... -
Evaluation of the Association of Polymorphisms With Palbociclib-Induced Neutropenia: Pharmacogenetic Analysis of PALOMA-2/-3.
Iwata, H; Umeyama, Y; Liu, Y; Zhang, Z; Schnell, P; et al. (WILEY, 2021-07-01)BACKGROUND: The most frequently reported treatment-related adverse event in clinical trials with the cyclin-dependent kinase 4/6 (CDK4/6) inhibitor palbociclib is neutropenia. Allelic variants in ABCB1 and ERCC1 might be ... -
Exceptional Response to AKT inhibition in breast cancer patients with germline PTEN mutations
Kingston, B; Pearson, A; Turner, N -
Exceptional Response to AKT Inhibition in Patients With Breast Cancer and Germline PTEN Mutations.
Kingston, B; Bailleux, C; Delaloge, S; Schiavon, G; Scott, V; et al. (American Society of Clinical Oncology (ASCO), 2019-01-01) -
First-Line Ipatasertib, Atezolizumab, and Taxane Triplet for Metastatic Triple-Negative Breast Cancer: Clinical and Biomarker Results.
Schmid, P; Turner, NC; Barrios, CH; Isakoff, SJ; Kim, S-B; et al. (AMER ASSOC CANCER RESEARCH, 2024-02-16)PURPOSE: To evaluate a triplet regimen combining immune checkpoint blockade, AKT pathway inhibition, and (nab-) paclitaxel as first-line therapy for locally advanced/metastatic triple-negative breast cancer (mTNBC). PATIENTS ... -
Functional antibody and T cell immunity following SARS-CoV-2 infection, including by variants of concern, in patients with cancer: the CAPTURE study.
Fendler, A; Au, L; Shepherd, STC; Byrne, F; Cerrone, M; et al. (NATURE PORTFOLIO, 2021-09-20)Patients with cancer have higher COVID-19 morbidity and mortality. Here we present the prospective CAPTURE study, integrating longitudinal immune profiling with clinical annotation. Of 357 patients with cancer, 118 were ... -
Gatekeeper Mutations and Intratumoral Heterogeneity in FGFR2-Translocated Cholangiocarcinoma.
Smyth, EC; Babina, IS; Turner, NC (AMER ASSOC CANCER RESEARCH, 2017-03-01)<b/>FGFR2 genetic translocations are frequent in cholangiocarcinoma, yet despite initial sensitivity to FGFR inhibitors in clinic, patients quickly become resistant to targeted therapies. The work published by Goyal and ... -
Genetic Alterations in the PI3K/AKT Pathway and Baseline AKT Activity Define AKT Inhibitor Sensitivity in Breast Cancer Patient-derived Xenografts.
Gris-Oliver, A; Palafox, M; Monserrat, L; Brasó-Maristany, F; Òdena, A; et al. (AMER ASSOC CANCER RESEARCH, 2020-07-15)PURPOSE: AZD5363/capivasertib is a pan-AKT catalytic inhibitor with promising activity in combination with paclitaxel in triple-negative metastatic breast cancer harboring PI3K/AKT-pathway alterations and in estrogen ... -
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT).
Condorelli, R; Mosele, F; Verret, B; Bachelot, T; Bedard, PL; et al. (ELSEVIER, 2019-03-01)Better knowledge of the tumor genomic landscapes has helped to develop more effective targeted drugs. However, there is no tool to interpret targetability of genomic alterations assessed by next-generation sequencing in ... -
Genomic profile of advanced breast cancer in circulating tumour DNA.
Kingston, B; Cutts, RJ; Bye, H; Beaney, M; Walsh-Crestani, G; et al. (NATURE PORTFOLIO, 2021-04-23)The genomics of advanced breast cancer (ABC) has been described through tumour tissue biopsy sequencing, although these approaches are limited by geographical and temporal heterogeneity. Here we use plasma circulating ... -
Genomic profiling and pre-clinical modelling of breast cancer leptomeningeal metastasis reveals acquisition of a lobular-like phenotype.
Fitzpatrick, A; Iravani, M; Mills, A; Vicente, D; Alaguthurai, T; et al. (Springer Science and Business Media LLC, 2023-11-16)Breast cancer leptomeningeal metastasis (BCLM), where tumour cells grow along the lining of the brain and spinal cord, is a devastating development for patients. Investigating this metastatic site is hampered by difficulty ... -
High p16 expression and heterozygous RB1 loss are biomarkers for CDK4/6 inhibitor resistance in ER+ breast cancer.
Palafox, M; Monserrat, L; Bellet, M; Villacampa, G; Gonzalez-Perez, A; et al. (NATURE PORTFOLIO, 2022-09-07)CDK4/6 inhibitors combined with endocrine therapy have demonstrated higher antitumor activity than endocrine therapy alone for the treatment of advanced estrogen receptor-positive breast cancer. Some of these tumors are ... -
High-Level Clonal FGFR Amplification and Response to FGFR Inhibition in a Translational Clinical Trial.
Pearson, A; Smyth, E; Babina, IS; Herrera-Abreu, MT; Tarazona, N; et al. (AMER ASSOC CANCER RESEARCH, 2016-08-01)UNLABELLED: FGFR1 and FGFR2 are amplified in many tumor types, yet what determines response to FGFR inhibition in amplified cancers is unknown. In a translational clinical trial, we show that gastric cancers with high-level ... -
Homologous recombination DNA repair deficiency and PARP inhibition activity in primary triple negative breast cancer.
Chopra, N; Tovey, H; Pearson, A; Cutts, R; Toms, C; et al. (NATURE PORTFOLIO, 2020-05-29)Triple negative breast cancer (TNBC) encompasses molecularly different subgroups, with a subgroup harboring evidence of defective homologous recombination (HR) DNA repair. Here, within a phase 2 window clinical trial, RIO ... -
Impact of Spontaneous Extracranial Bleeding Events on Health State Utility in Patients with Atrial Fibrillation: Results from the ENGAGE AF-TIMI 48 Trial.
Wang, K; Li, H; Kwong, WJ; Antman, EM; Ruff, CT; et al. (WILEY, 2017-08-11)BACKGROUND: The impact of different types of extracranial bleeding events on health-related quality of life and health-state utility among patients with atrial fibrillation is not well understood. METHODS AND RESULTS: The ... -
Inactivating NF1 Mutations Are Enriched in Advanced Breast Cancer and Contribute to Endocrine Therapy Resistance.
Pearson, A; Proszek, P; Pascual, J; Fribbens, C; Shamsher, MK; et al. (AMER ASSOC CANCER RESEARCH, 2020-02-01)PURPOSE: Advanced breast cancer (ABC) has not been subjected to the same degree of molecular scrutiny as early primary cancer. Breast cancer evolves with time and under the selective pressure of treatment, with the potential ... -
Incorporating clinicopathological and molecular risk prediction tools to improve outcomes in early HR+/HER2- breast cancer.
Curigliano, G; Dent, R; Llombart-Cussac, A; Pegram, M; Pusztai, L; et al. (NATURE PORTFOLIO, 2023-06-28)Stratification of recurrence risk is a cornerstone of early breast cancer diagnosis that informs a patient's optimal treatment pathway. Several tools exist that combine clinicopathological and molecular information, including ... -
Ipatasertib plus paclitaxel for PIK3CA/AKT1/PTEN-altered hormone receptor-positive HER2-negative advanced breast cancer: primary results from cohort B of the IPATunity130 randomized phase 3 trial.
Turner, N; Dent, RA; O'Shaughnessy, J; Kim, S-B; Isakoff, SJ; et al. (SPRINGER, 2021-12-03)PURPOSE: PI3K/AKT pathway alterations are frequent in hormone receptor-positive (HR+) breast cancers. IPATunity130 Cohort B investigated ipatasertib-paclitaxel in PI3K pathway-mutant HR+ unresectable locally advanced/metastatic ... -
Long-Term Pooled Safety Analysis of Palbociclib in Combination with Endocrine Therapy for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Updated Analysis with up to 5 Years of Follow-Up.
Finn, RS; Rugo, HS; Gelmon, KA; Cristofanilli, M; Colleoni, M; et al. (WILEY, 2021-03-10)BACKGROUND: Previous studies demonstrated the tolerability of palbociclib plus endocrine therapy (ET). This analysis evaluated safety based on more recent cutoff dates and a longer palbociclib treatment exposure. PATIENTS ... -
Long-term Pooled Safety Analysis of Palbociclib in Combination With Endocrine Therapy for HR+/HER2- Advanced Breast Cancer.
Diéras, V; Rugo, HS; Schnell, P; Gelmon, K; Cristofanilli, M; et al. (OXFORD UNIV PRESS INC, 2019-04-01)BACKGROUND: Palbociclib administered with endocrine therapy was tolerable when the overall incidence of toxicities was assessed separately for three PALOMA studies. This study analyzed pooled, longer-term PALOMA safety ...